Interventional Cardiology Devices – Market Insights – United States

The US interventional cardiology device market is highly competitive and poised for growth, driven by increasing PCI volumes for complex CAD cases and the adoption of innovative devices and technologies. Favorable clinical evidence, particularly for coronary IVL, will continue to propel the market forward. Additionally, the adoption of novel products and diagnostic methods is expected to expand the eligible patient population and support continued market growth in coming years.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for IC devices in the US, with market projections from 2019 through 2033.

The increasing prevalence of complex CAD cases will drive demand for innovative devices and result in a higher proportion of complex PCIs.

Which factors are contributing to the rising prevalence of complex CAD cases?

How will the demand for innovative devices change as the proportion of complex CAD cases increases?

The coronary stent market is a highly competitive space, with the leading companies continuing to launch updates to their flagship devices.

What are the market share dynamics among the three major competitors in the highly lucrative DES device market?

Which competitive strategies are the major companies implementing to gain market share in this market, and how are ASPs being impacted by the strong competition?

What is the developmental pipeline for next-generation of BRS and which technologies are companies utilizing as a stopgap until BRS technology is ready for patient use?

The expansion of intravascular lithotripsy use is bolstering the IC device market.

How has the commercialization of coronary lithotripsy impacted the use of other products in the interventional cardiology space?

How is reimbursement changing for coronary lithotripsy, and how will this affect adoption of this technology?

The adoption of premium-priced devices and new diagnostic methods will impact procedural success rates and overall PCI volumes in the US IC device market.

What is the impact of the latest generation of alternative coronary physiology modalities, such imaging-based FFR_angio and FFR_CT, on existing intravascular imaging technologies, including traditional FFR and IVUS?

What is the expected impact of emerging balloon-based technologies such as DCBs?

How will new clinical trial results impact IC device segments, procedures, competitors, and products?